BCAL Diagnostics (ASX:BDX) Total Payout Yield % : 0.00 (As of Jun. 06, 2024)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

BCAL Diagnostics's current Total Payout Yield % is 0.00%.

BCAL Diagnostics Total Payout Yield % Historical Data

The historical data trend for BCAL Diagnostics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Total Payout Yield % Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Total Payout Yield %

-56.70

-0.34

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Total Payout Yield %	Get a 7-Day Free Trial			-109.67	-0.36	-	-	-21.73

Competitive Comparison of BCAL Diagnostics's Total Payout Yield %

For the Diagnostics & Research subindustry, BCAL Diagnostics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's Total Payout Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Total Payout Yield % falls into.

BCAL Diagnostics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

BCAL Diagnostics's Total Payout Yield % for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Market Cap
	=	- (0	+	0.05	+	0)	/	14.86205
	=	-0.34%

BCAL Diagnostics's annualized Total Payout Yield % for the quarter that ended in Dec. 2023 is calculated as

Total Payout Yield %	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	*	Annualized Factor	/	Market Cap
	=	- (-0.272	+	3.006	+	0)	*	2	/	25.1639
	=	-21.73%

BCAL Diagnostics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.

BCAL Diagnostics Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Total Payout Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.